Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, is currently primarily used in recipients with renal dysfunction post-LT, intolerable adverse reactions to calcineurin inhibitors (CNIs), and a risk of tumor recurrence. Here, MTOR is linked to neoplasm.